Aileron Therapeutics (NASDAQ:ALRN) Stock Gains Momentum: Should You Still Buy?

August 12, 2021

Aileron Therapeutics (NASDAQ:ALRN) is up 4% in pre-market after announcing its Q2 2021 financial results and business highlights. Its CEO Manuel Aivado stated that it continues executing against its clinical development strategy thanks to its strong balance sheet.  In addition, the company is advancing selective chemoprotection for p53-mutated cancer patients. During the quarter, the company initiated its first double-blind, randomized and placebo-controlled clinical study of ALRN-6924 for p53 mutated NSCL…

Read More >>